BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 22832091)

  • 1. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo E; Ravaud A; Bellmunt J
    Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
    Felici A; Bria E; Tortora G; Cognetti F; Milella M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
    Kruck S; Bedke J; Kuczyk MA; Merseburger AS
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
    Calvo E; Grünwald V; Bellmunt J
    Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials.
    Ghatalia P; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):251-63. PubMed ID: 25900071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.
    Larkin J; Swanton C; Pickering L
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):639-49. PubMed ID: 21504330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
    Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.